Last C$0.16 CAD
Change Today +0.005 / 3.33%
Volume 5.6K
APC On Other Exchanges
As of 1:43 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

advanced proteome therapeuti (APC) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/14 - C$0.39
52 Week Low
12/19/13 - C$0.14
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

advanced proteome therapeuti (APC) Related Businessweek News

No Related Businessweek News Found

advanced proteome therapeuti (APC) Details

Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company. It focuses on the development of a patent-pending technology that combines multiple anti-cancer therapies in a single agent to directly target cancer tumors. The company is headquartered in Boston, Massachusetts.

advanced proteome therapeuti (APC) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $175.0K
Chief Financial Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

advanced proteome therapeuti (APC) Key Developments

Advanced Proteome Therapeutics Corporation Announces Positive Results in Combination Cancer Immunotherapy

Advanced Proteome Therapeutics Corporation (APC) reported results from its current round of experiments that not only reinforce previous evidence of the immunotherapeutic properties of APC's protein modification technology, but hold forth the possibility of synergistic effects with other immunotherapies while heralding the entry of a new and potentially powerful approach in the arsenal of anticancer weaponry. Over the past year, the company has demonstrated that APC's technology has the ability to overcome immune tolerance of certain tumors that have evolved mechanisms to evade attack by the body's immune system. APC has been able to enhance the affinity for target cancer cells of a natural human protein that possesses demonstrable anticancer activity, by modifying the protein chemically in a variety of ways. Indeed, various modifications of the protein, have translated into greater antitumor potency in animal models. Now, results from combination therapy with checkpoint inhibitors have demonstrated very promising results with the first molecule tested from APC's inventory of modified proteins. In experiments with animal models with tumor implants carried out with APC's academic collaborators, checkpoint inhibitors by themselves only slowed tumor growth, but did not cause tumor regression. By marked contrast, in parallel experiments using a combination of a checkpoint inhibitor with APC's D5 protein modification, the tumors were eradicated. As well, subsequent experiments showed that the animals were immune to rechallenge by the same tumor. APC plans to rapidly capitalize on these findings by expanding testing of its protein modifications to diverse treatment tumor models (that is breast, colon, lung). The company is currently in negotiations with contract research organizations (CROs) to pursue such additional testing over the next few months, and expects to conclude an agreement shortly. The context for these experiments is an unprecedented and development in cancer drug research, the robust single agent activity that has been observed with immune checkpoint inhibitors, which are regarded as the next big wave of cancer therapies. In contrast to traditional therapy, by mobilizing a patient's immune system, immunotherapies have been durable, rendering many patients cancer-free for years, and have persisted without off-target toxicity. Unfortunately, the majority of patients do not respond or will have an incomplete response to such checkpoint inhibitors by themselves. It is now established that such immune modulating antibody-based immunotherapies offer more benefit to the patient by being administered in combination with other forms of cancer management or in tandem with other immune modulating molecules. This approach is a basis for APC's current focus and has engendered a massive effort on the part of the pharmaceutical industry to discover such clinically viable drug combinations and bring them to market.

Advanced Proteome Therapeutics Corporation, Annual General Meeting, Jul 22, 2014

Advanced Proteome Therapeutics Corporation, Annual General Meeting, Jul 22, 2014., at 10:00 Pacific Standard Time. Location: English Bay Room, Computershare Investor Services Inc. , 3rd Floor, 510 Burrard Street. Agenda: To receive the audited financial statements of the company for its financial year ended July 31, 2013 and the report of the auditors thereon; to set the number of directors of the company to be elected at three; to elect directors of the company for the ensuing year; to appoint auditors of the company for the ensuing year and to authorize the directors to fix their remuneration for the ensuing year; to ratify and approve adoption of the company's stock option plan; to ratify and approve adoption of the company's advance notice policy; and to transact such other business as may properly come before the meeting or any adjournment thereof.

Advanced Proteome Therapeutics Updates Ongoing Activities

Advanced Proteome Therapeutics Corporation has prepared several molecules using its patent-pending technologies, which represent the first of several series that the Company has conceived as potential anti-cancer agents, each of which has its own individual attributes for drug development. In the first round of testing by APC and its collaborators, all members of the first series exhibited high affinity for specific cancer cells and no obvious toxic effects on healthy cells. The unmodified protein by itself demonstrated the ability to retard tumor growth, and a conjugate of the protein prepared by APC was shown to concentrate in tumors. Following on these tests, the company has now discovered that two members of the first series, which have been selected for further testing in animal models of cancer, have demonstrated statistically significant retardation of tumor growth in mice and possess higher affinity than the unmodified protein toward specific cancer cells. These positive findings suggest that its chemical modifications to the protein, which in unmodified form activates animal immune systems to destroy tumor cells, may be used to enhance the activity of the protein itself, and achieve therapeutic benefits for the Company's proprietary molecular assets. In line with company plans to select a lead member of at least three series, with all deliberate speed, for advanced preclinical development and deal-making, testing has now begun on the second series of protein modifications and testing on the third series is expected to begin shortly. The company will carry out animal studies over the next few months to optimize the properties of its most effective and commercially attractive candidates. This process is expected to result in the selection of candidates with the mix of properties to speed development. The Company plans, concurrently, to seek out corporate Partners in the pharmaceutical industry for joint efforts or licensing deals, which would support company programs and advance eligible candidates toward clinical trials as rapidly as possible according to strategic plans. Advanced Proteome Therapeutics has been applying its enabling Foundation Trinity(TM) Technology to proteins targeted for the treatment of cancers. Advanced targeted therapies are designed to attack primarily cancer cells and are expected to dominate the anti-cancer therapeutics' market in the near future. The company's goals are not only to employ therapy targeted for tumor cells, but also to deliver combination therapy in a single, pure therapeutic agent. To achieve this end, it has been the Company's intention to utilize a unique protein (and related systems), not only as a delivery vehicle to tumor cells, but also as a scaffold upon which to attach each anti-cancer entity to its own specific site on the protein surface - both key to efficient manufacturing and product development. The protein vehicle has emerged as a potential immunotherapeutic as it is implicated in activating the immune system to attack and help clear tumor cells. Immunotherapy is perhaps the most powerful current approach to cancer, and one of great commercial interest to the pharmaceutical industry.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APC:CN C$0.16 CAD +0.005

APC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for APC.
View Industry Companies

Industry Analysis


Industry Average

Valuation APC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 24.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADVANCED PROTEOME THERAPEUTI, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at